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Paclitaxel-coated balloon fistuloplasty
versus plain balloon fistuloplasty only to
preserve the patency of arteriovenous
fistulae used for haemodialysis (PAVE):
study protocol for a randomised controlled
trial
Narayan Karunanithy1, Irene Rebollo Mesa2, Anthony Dorling3,4, Francis Calder4, Konstantinos Katsanos1,
Vikki Semik3, Emily Robinson2, Janet Peacock5, Neelanjan Das6, Colin Forman7, Sarah Lawman8, Kate Steiner9,
C Jason Wilkins10 and Michael G Robson3,4*
Abstract
Background: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological
balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported
to be 40–50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may
be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae.
Methods/design: We have designed a multicentre, double-blind randomised controlled trial to test the superiority
of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous
fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a
clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual
stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in
the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the
time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a
clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the
treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment.
Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the
total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research.
Discussion: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional
paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of
arteriovenous fistulae used for haemodialysis.
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Background
The 2012 UK Renal Registry report (www.renalreg.com)
found that 43.9 % of patients with end-stage kidney dis-
ease in the UK are on haemodialysis. This equated to 365
patients per million population in the UK in 2011. This
number has increased every year with an overall increase
of 3.6 % from 2006 to 2011. In order to perform haemodi-
alysis, reliable vascular access is essential. It is universally
agreed that native arteriovenous fistulae (AVF) are super-
ior to synthetic arteriovenous grafts (AVGs) and tunnelled
central venous catheters for haemodialysis access. AVFs
and AVGs have limited lifespans. Data from the Dialysis
Outcomes and Practice Study (DOPPS) showed that in
the US the 1-year patency for AVFs and AVGs are 68 %
and 49 % respectively. In Europe, 1-year AVF survival was
somewhat better at 83 % but there is still a need for
improvement [1].
Problems with vascular access are an important cause of
morbidity and mortality in haemodialysis patients. In the
US, it has been estimated that $1 billion per year is spent
on vascular access and its complications [2]. A recent sur-
vey in the UK found that haemodialysis patients occupy
320,000 bed days per year, with 30 % of admissions related
to vascular access (Renal Association vascular access
audit, available at www.renal.org). When thrombosis or
stenosis occurs in an AVF or AVG, a central venous cath-
eter may be used for several months until another AVF or
AVG is formed and becomes usable. Data from the US
have shown that the risk of invasive infection is increased
100-fold in haemodialysis patients compared to the gen-
eral population. Eighty-five percent of those diagnosed
with an infection have an invasive device in situ. Ninety
percent of those diagnosed with an infection require hos-
pitalisation and there is a 17 % associated mortality [3]. It
is, therefore, imperative to preserve each AVF or AVG for
as long as possible and to minimise the use of central ven-
ous catheters.
The initial therapy for a stenosis in an AVF is radio-
logical fistuloplasty. A major concern, however, is the
longevity of this effect. Turmel-Rodrigues et al. reported
the outcomes of interventional salvage of dysfunctional
and thrombosed haemodialysis circuits [4]. There were
220 cases in the dysfunctional AVF group. The 6-, 12-,
and 24-month primary patency (AVF working with no re-
peat intervention) reported rates were 67 %, 51 % and
37 % for forearm AVF and 57 %, 35 % and 24 % for upper
arm AVF respectively. More recently Bountouris et al.
reported the outcomes after 159 percutaneous translumi-
nal angioplasties (PTAs) in AVFs. The primary patency
rates at 6, 12 and 24 months were 61 %, 42 % and 35 %
respectively [5]. Primary assisted patency rates (AVF work-
ing regardless of repeat intervention) were 89 % and 85 %
at 6 and 12 months respectively. Although there have
been some exceptions [6, 7], most other studies have
reported similar primary patency rates of around 40–50 %
at 1 year [8–10]. Hence, more durable interventions are
required to reduce restenosis rates.
In addition there is a need to better understand the
cellular processes involved in the development of sten-
oses and the responses that occur following intervention.
Neointimal hyperplasia is characterised by expansion of
alpha smooth muscle actin-positive myofibroblasts in
the neointima which leads to stenoses in the venous seg-
ments of AVFs [11]. In arteries, the contribution of bone
marrow-derived cells to tissue repair depends on the
nature and severity of injury [12]. The contribution of
bone marrow cells to venous neointimal hyperplasia is
not resolved and the data from animal studies are con-
flicting. Two studies using bone marrow transplantation
with cells containing a green fluorescent protein (GFP) or
β-galactosidase reporter gene, have suggested a minimal
contribution of bone marrow-derived cells in mouse and
rat models respectively [13, 14]. However, a further study
employing a murine vein graft has suggested that at least
20 % of neointimal cells may be bone marrow-derived
[15]. GFP-positive cells were detected by a more sensitive
polymerase chain reaction (PCR) method and these tech-
nical differences were suggested as a reason for discrepan-
cies with other studies.
In addition to these conflicting data on the origin of
neointimal cells, it should be noted that none of the pre-
vious reports induced vein injury in a way that mirrors
the changes induced by angioplasty. Instead, most have
focussed on the development of primary stenosis in ven-
ous conduits undergoing arterialisation where endothe-
lium is ‘traumatised’ or activated by changes in the flow
characteristics of the arterial blood to which it becomes
exposed. Given the data from arterial studies, a contri-
bution from bone marrow cells to the alpha smooth
muscle actin-producing cells in the hyperplastic neoin-
tima of a dysfunctional arteriovenous fistula is highly
likely with the degree of trauma to the endothelium that
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would follow angioplasty. Angioplasty causes vessel wall
damage with rupture of the junction between the intima
and the media, with a burst of proliferation and repair.
Much of our understanding of aggressive neointimal for-
mation in this context comes from arterial studies [16],
but similar pathology and an increase in proliferation has
been shown in AVFs following venous angioplasty [17].
Paclitaxel exerts an anti-proliferative effect by interfer-
ing with cell microtubule function [18]. Systemic adminis-
tration of paclitaxel after angioplasty in the rat carotid
artery showed that a significant reduction in neointimal
proliferation could be achieved at doses much lower than
antineoplastic levels [19]. In rat and human cultured cell
models, paclitaxel inhibited vascular smooth muscle cell
migration and proliferation [19, 20], consistent with its
effects in vivo. As an alternative to systemic therapy, local
drug delivery offers the advantages of allowing high local
concentrations of drug at the treatment site while mini-
mising systemic toxic effects. Proof of this possibility was
initially shown using paclitaxel-coated stents in pig coron-
ary arteries [21].
Recent advances in technology have allowed angioplasty
balloons to be coated with paclitaxel. This allows local
delivery of paclitaxel to the site of stenosis. A number of
multicentre, randomised controlled trials (RCTs) in the
coronary and peripheral arterial circulation have estab-
lished the positive benefit of drug-coated balloons (DCBs)
[22, 23]. A small pilot study has suggested efficacy in dia-
lysis patients [24, 25]. In this study, 40 patients with dys-
functional AVFs or AVGs were randomised to receive
either DCB or plain balloon angioplasty (PBA). Primary
unassisted patency (defined angiographically as a binary
readout of less than 50 % stenosis) in the DCB group was
significantly better than the PBA group at 6 (70 % versus
25 %) and 12 months (35 % versus 5 %, p <0.001) respect-
ively. This study may be criticised on a number of points.
These include the use of an angiographic rather than a
clinical endpoint, the lack of blinding and independent
angiographic core laboratory analysis and the very small
sample size originally intended to test non-inferiority only
(with a wide 15 % non-inferiority limit). In addition, a
range of balloons was used in the control group for post
dilatation after the paclitaxel-coated balloons, and these
were not universally high pressure and non-compliant.
This may have added variability to the outcome. Further-
more, the inclusion of both AVFs (35 %) and AVGs (65 %)
may have resulted in significant confounding given the
difference in survival rates associated to the two types of
access. Despite these limitations, the results suggested that
a further study of efficacy is warranted, which is what we
propose here.
The PAVE trial is a large-scale RCT designed to test
superiority of DCBs in native haemodialysis access cir-
cuits. Further, the impact on patient quality of life will
be assessed. Patient blood samples will also be collected
within the setting of the clinical trial. This will form an
important resource for future laboratory-based studies
on biomarkers and AVF outcomes.
Methods/design
Trial objectives
The purpose of this RCT is to compare the efficacy of
additional paclitaxel-coated balloon fistuloplasty versus
plain balloon fistuloplasty only to preserve the patency
of arteriovenous fistulae used for haemodialysis.
Primary endpoint
Time to end of target lesion primary patency
This is defined as patency with no re-intervention to the
area 5 mm proximal to, within, and 5 mm distal to, the
index treatment segment. Target lesion primary patency
ends when any of the following occur: (1) clinically
driven re-intervention to the treatment segment, (2)
thrombotic occlusion that includes the treatment seg-
ment, (3) surgical intervention that excludes the treat-
ment segment from the access circuit, (4) abandonment
of the AVF due to an inability to re-treat the treatment
segment.
In order to confirm that there is a significant stenosis
prior to fistuloplasty, duplex ultrasound is encouraged
but is not mandatory. It is not mandatory as patients are
not randomised until eligibility is angiographically
confirmed.
After the study treatment, occasionally there may be
recoil or rupture necessitating further balloon angioplasty
or stent placement. Providing further angioplasty and/or
stent placement achieves a residual stenosis of less than
30 %, these patients will remain in the study.
Referral for a repeat procedure will originate from the
clinical team who are unaware of whether the patient
received treatment with a paclitaxel-coated balloon or
uncoated control balloon.
A different radiologist to the one performing the index
procedure will perform repeat procedures when possible
but it is not possible to guarantee this. Therefore, the
radiologist performing the repeat procedure may have
knowledge of whether the patient was treated with DCB
or placebo.
In order to ensure that there is no bias in the final de-
cision to proceed with the repeat intervention in pa-
tients who have not yet reached the primary endpoint,
any pre-procedure fistulogram prior to potential re-
intervention will undergo independent core laboratory
analysis. This will allow confirmation that a significant
stenosis was found in all patients who received a repeat
intervention.
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Secondary endpoints
1. Angiographically determined late lumen loss.
This is the difference between the diameter of the
treatment segment post procedure and the diameter
at 6 months as measured by an independent core
laboratory. If a patient has a repeat procedure to
the treatment segment before 6 months, then the
pre-intervention images will be used for analysis and
a fistulogram at 6 months will not be performed
2. The rate of angiographic binary re-stenosis.
This is defined as the incidence of stenosis of at
least 50 % within the treated lesion at the 6-month
follow-up fistulogram. If a patient has a repeat
procedure to the index lesion before 6 months, then
the pre-intervention images will be used for analysis
and a fistulogram at 6 months will not be performed
3. Time to end of access circuit primary patency.
The access circuit is defined as starting at the
arterial anastomosis and ending at the cavoatrial
junction. Access circuit primary patency ends when
any of the following occur: (1) access circuit
thrombosis, (2) an intervention (either radiological
or surgical) anywhere in the access circuit, or (3) the
access circuit is abandoned due to an inability to
treat any lesion
4. Time to end of access circuit cumulative patency.
Access circuit cumulative patency ends when the
AVF is abandoned, regardless of radiological or
surgical intervention, with or without a thrombotic
event. Multiple/repetitive treatments for stenoses
that restore patency are compatible with cumulative
patency
5. Procedural success (residual stenosis of 30 % or less
on completion fistulogram II, after the study
treatment)
6. Number of thrombotic events
7. Total number of interventions
8. Adverse events (e.g. fistula rupture, infection)
9. Patient quality of life as assessed by the EuroQol
EQ-5D generic health survey, and the disease-
specific Patient (or Palliative care) Outcome Scale
symptom score-renal (POS-S Renal) [26].
Trial design
The study design used to achieve this will be a multicentre,
double-blind RCT. We will recruit 211 patients over a 2-
year period from an anticipated six centres. We do not
anticipate any differences in relevant clinical characteristics
between centres. However, the level of difference will be
tested at the analysis stage and trial centre will, therefore,
be included as a possible covariate in the primary analysis
model. Patients will be followed up for a minimum of 1 year,
and all patients will continue in the study until the last
patient has completed 1 year of follow-up. Figure 1 shows
the trial flow chart.
Trial statistics
Analysis of primary outcome
To test the superiority of the paclitaxel-coated balloon
treatment group compared to placebo balloon in target
lesion primary patency (TLPP) survival we will use Cox
proportional hazards regression, on an intention-to-treat
basis. Primary analysis will be repeated using multivari-
ate Cox regression for the adjustment of the treatment
effect size for the effect of known clinical covariates and
minimisation factors. Model components considered in
the primary model will include previous radiological
intervention in the access circuit; trial centre; whether
the patient is on haemodialysis or not at study entry;
trial arm; observed study time (length of time between
patient entering and exiting study); and a trial arm ×
observed time interaction term. The interaction term
allows for variable follow-up time effects. Patients with
TLPP at the end of follow-up will be considered cen-
sored, as will those who receive a renal transplant,
switch to peritoneal dialysis or are lost to follow-up be-
fore the study end. Kaplan-Meier plots, hazard ratio
(HR) and its confidence interval will be used to describe
the results.
Analysis of secondary outcomes
Effects on secondary outcomes will be analysed using the
same strategy for time-to-event variables, and generalised
linear models for binary and continuous outcome mea-
sures, adjusting for the effects of relevant covariates when
appropriate. Continuous variables will be checked for nor-
mality, transformed if necessary or otherwise analysed using
a Wilcoxon signed-rank test for independent samples.
Missing values and drop-outs
Withdrawal from trial follow-up (attrition rate) will be
reported by intervention group, including reasons for
withdrawal. The proportions of participants missing
each variable will be summarised in each arm and at
each study visit. If necessary, multiple imputation will be
used for the imputation of missing values in baseline
variables and secondary outcomes. Patients with TLPP
at the end of follow-up will be considered censored, as
will those who receive a renal transplant, switch to peri-
toneal dialysis or are lost to follow-up before the study
end. The baseline characteristics and adverse events
(AEs) of patients lost to follow-up will be compared to
those with complete follow-up data. The relationship be-
tween these and missing data will be investigated graph-
ically to see if baseline characteristics or AEs predict
missing values, i.e. drop-outs are not random. Should
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any baseline variables be predictive of missing values
then these will be included in the primary analysis Cox
regression models as further covariates.
For non-time-to-event outcomes, missing post-
randomisation assessments will be dealt with by fit-
ting generalised linear models to all the available data
using maximum likelihood methods. Such an approach
provides valid inferences under the assumption that the
missing data mechanism is ignorable (or missing at ran-
dom (MAR)). This allows for missingness at later times to
be predicted by outcome values at earlier times. However,
if post-treatment variables, such as compliance with study
procedures, are found to be predictive of drop-out, mul-
tiple imputation will be considered.
Interim analysis
Interim analysis of the primary outcome will be per-
formed three times throughout the study based on
the cumulative number of failures of the treatment
area, i.e. after 27, 54 and 81 events, expected approxi-
mately at 9, 14 and 19 months of study under the
null hypothesis, and at months 11, 17, and 23 under
the alternative hypothesis. Group sequential stopping
boundaries have been calculated using a Lan-DeMets
spending function (with O’Brien-Fleming parameters),
to allow early stopping for rejection of the null or the
alternative hypotheses. Stopping in case of boundary
crossing is non-binding.
Model assumption checks
In order to assess the adequacy of the Cox regression
models for the primary outcome and time-to-event sec-
ondary outcomes, the main assumption to test for is
proportionality; the Kaplan-Meier plots will be used to
check if the curves for the two trial arms are the same
shape, and if the separation of the curves remains
proportionate throughout the analysis period. In
addition, time-dependent covariates will be generated
by creating interactions of the predictors and function
of survival time; if these are significant then the pre-
dictors are not proportional. If the assumption for
proportionality is violated then the consequence this
has on the results can be checked. The Cox model
can be stratified according to the variables with non-
proportional hazards to see whether this changes the
HRs for the variables of interest; if it still does, then
Fig. 1 Trial flow chart showing patient progression through the study
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it may be necessary to use an alternative model. One
parametric alternative is the Royston-Parmar model,
which is more flexible and can fit a non-proportional
hazards model. For the other secondary outcomes
regression residuals will be plotted to check for nor-
mality and outliers, where applicable.
Sample size, selection and withdrawal of subjects
For the definition of the survival curve in the placebo
balloon group, we assumed target lesion primary patency
rates of 61 %, 42 %, and 35 % at 6, 12 and 24 months
respectively. This was consistent with published results [7]
and with our own audit data. A HR of 0.5 was chosen as
the minimum clinically relevant effect size. Katsanos et al.
[24] found a HR of 0.3 for TLPP at 6 months; however,
the confidence interval was broad and the effect size is
expected to be closer to the null when AVGs are excluded.
Based on these assumptions, it is expected that the
paclitaxel-coated balloon group will show 78 %, 65 %, and
59 % survival rates of TLPP at 6, 12 and 24 months
respectively. Recruiting 211 patients, with variable follow-
up, a minimum follow-up of 1 year, and three interim
analyses, will provide 94 % power to detect a statistically
significant difference between the two groups in TLPP
survival rates with a two-sided 5 % type I error rate. It is
expected that 108 patients will experience fistula failure
during the follow-up period.
The required sample size has been estimated assuming
cumulative 10 % drop-out in each treatment arm by the
end of the study, and recruitment of 2 patients per month
(ppm) during the first 3 months, 8 ppm up to 7 months,
and 12 ppm onwards. The expected accrual duration will
be 22 months, and the maximum study duration (includ-
ing follow-up) 34 months. We do not anticipate patients
completely withdrawing from the trial as the primary
endpoint data are collected primarily from clinical re-
cords. The 10 % drop-out estimate is based primarily on
switching to peritoneal dialysis, receiving a transplant, or
death.
The inclusion and exclusion criteria are summarised
in Table 1.
Criteria for premature withdrawal
Participants have the right to withdraw from the study
at any time for any reason.
Participants will be withdrawn from the study if any of
the following occur:
 Death of participant
 Participant receives a transplant
 Participant is changed from haemodialysis to
peritoneal dialysis
The principal investigator (PI) also has the right to
withdraw patients from the study in the event of inter-
current illness, AEs, serious adverse events (SAEs), proto-
col violations, administrative reasons or other reasons, e.g.
the participant is no longer being treated at a hospital
included in the study.
It is understood by all concerned that an excessive rate
of withdrawals can render the study uninterpretable;
therefore, unnecessary withdrawal of patients should be
avoided. Should a patient decide to withdraw from the
study, all efforts will be made to report the reason for
withdrawal as thoroughly as possible. Participants who
wish to withdraw from ‘treatment’ will be asked to con-
firm whether they are still willing to provide study-specific
data and samples for scientific laboratory analysis accord-
ing to the trial protocol.
Table 1 Inclusion and exclusion criteria for the trial
Inclusion criteria Exclusion criteria
1. Patients (18 years or over) who have a native AVF in the arm 1. Patient unable to give informed consent
2. An indication for a fistuloplasty as determined by the local clinical team 2. Patient unwilling or unable to comply with all study-related procedures
3. The access circuit is free of synthetic graft material or stents 3. Systemic or local (to the fistula) infection treated for less than 10 days
prior to the study procedure
4. A reduction of vessel diameter ≥50 % measured angiographically and
reference diameter of the outflow vein ≥4 mm and less than the size of
the largest available DCB
4. Synchronous venous lesion, with a reduction of vessel diameter of
≥50 % measured angiographically, in the same access circuit
5. A residual stenosis ≤30 % after plain balloon fistuloplasty 5. Location of stenosis central to the thoracic inlet
6. Thrombosed (failed) access circuit at time of treatment
7. Women who are breastfeeding, pregnant or are intending to become
pregnant or men intending to father children, within 2 years of study treatment
8. Known hypersensitivity or contraindication to contrast medium which
cannot be adequately premedicated
9. Known hypersensitivity or contraindication to paclitaxel
AVF arteriovenous fistula, DCB drug-coated balloon
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Screening procedures
Patients who may be eligible will be identified in a vascular
access clinic and assessed by surgeons, specialist nurses
and nephrologists.
In order to confirm that there is a significant stenosis
prior to angiography, a duplex ultrasound is encouraged
but is not mandatory.
At least 24 hours after being given the patient informa-
tion sheet and before entering the interventional suite,
consent will be taken and eligibility criteria as listed above
in Table 1 will be assessed. Inclusion criteria 1–3 will be
confirmed and exclusion criteria 1–3 and 6–9 will be
assessed.
The radiologist who will perform the procedure will be
informed that the patient is potentially eligible for the
study.
All procedures will be performed in a dedicated inter-
ventional radiology suite equipped with digital subtraction
angiogram, image overlay/roadmap post-processing cap-
abilities and ability to capture still and video DICOM file
data.
The pre-procedure fistulogram
This will be take place immediately prior to the plain
balloon fistuloplasty. It will be performed through a sheath
or cannula placed in the dialysis circuit according to the
specifications summarised in Table 2.
The radiologist will assess inclusion criteria 3 and 4,
and exclusion criteria 4 and 5, to decide if the patient re-
mains eligible for the study.
The plain balloon fistuloplasty procedure
Prior to treatment 3000–5000 IU of heparin is adminis-
tered. For all patients treatment has two components. The
fistuloplasty procedure is performed with a dedicated
plain balloon (Bard Dorado) ensuring the following cri-
teria are met:
1. Sized to nominal vein diameter
2. Up to 24 Atm of pressure to ensure obliteration of
the lesion waist
3. Minimum duration of balloon inflation of 1 minute
If further plain balloon fistuloplasty treatment is re-
quired, then this may be administered twice more
only prior to the study treatment.
Completion fistulogram I is performed after the plain
balloon fistuloplasty to ensure adequate therapy accord-
ing to the specifications in Table 3.
The radiologist will assess completion fistulogram I
and decide if the residual stenosis is 30 % or less (in-
clusion criteria 5). If this is the case the patient will
proceed to randomisation, and if not the patient will
be excluded.
Randomisation procedures
Randomisation will be at the level of the individual
participants, minimising on the radiologist performing
the study procedure, whether the participant is currently
on haemodialysis or not, and whether the participant
has had a previous radiological intervention in the access
circuit or not. This is performed with an 80 % probabil-
ity of allocating to the arm which reduces the imbalance.
The allocation sequence will be generated dynamically.
This way, the next allocation will only be generated and
become known upon actioning a request from the study
site staff.
Table 2 Specifications for the pre-procedure fistulogram and
the 6-month protocol fistulogram
It will be performed in a dedicated interventional radiology suite
equipped with digital subtraction angiogram, image overlay/roadmap
post-processing capabilities and ability to capture still and video DICOM
file data.
It will be performed through a sheath or cannula placed in the dialysis
circuit according to the following specifications:
1. All fistulograms performed as digital subtraction acquisitions at three
frames per second
2. The entire access circuit from anastomosis to central vein covered in
up to three stages
3. Medial epicondyle of humerus as visible bony landmark on lower arm
acquisition; acromioclavicular joint on upper arm and central
acquisitions
4. Measurement ruler in view
5. Lower arm acquisition to include:
(a) Anteroposterior projection of anastomosis
(b) Oblique projection of anastomosis (specify oblique and craniocaudal
angulation)
6. On the acquisition that best demonstrates the target lesion, the
following measurements are made:
(a) Peripheral (close to anastomosis) reference vessel diameter
(b) Minimum lumen diameter (MLD)
(c) Central reference vessel diameter
Specifications for (a) the pre-procedure fistulogram, (b) the 6-month protocol
fistulogram, and (c) fistulograms performed for a clinical indication in patients
who have: (i) not yet reached the primary endpoint, and (ii) are referred for a
potential re-intervention by the radiologist who performed the study
treatment and so is not blinded to this
Table 3 Specifications for completion fistulograms I and II
1. All fistulograms performed as digital subtraction acquisitions at three
frames per second
2. Acquisition that demonstrates the target lesion is matched as close as
possible to the respective pre-procedure fistulogram acquisition
3. Measurement ruler in view
4. The following measurements are made:
(a) Peripheral (close to anastomosis) reference vessel diameter
(b) Minimum lumen diameter (MLD)
(c) Central reference vessel diameter
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Minimisation will be implemented using an independent
web-based randomisation system hosted at the UKCRC-
registered clinical trials unit at KCL. Site staff will access
the service via www.ctu.co.uk using a computer in the
angiography room or an office nearby. It will be performed
by the radiologist or their nominee who will log into the
system, enter the participant ID number, initials, date of
birth, recruiting radiologist, whether the participant is cur-
rently on haemodialysis or not, and whether the participant
has had a previous radiological intervention in the access
circuit or not. Nominees must not be clinicians or nurses
who may decide to refer the patient for re-intervention.
Each randomiser will have a unique user access, provided
by the Clinical Trials Unit (CTU) upon the authorisation of
the trial manager, once the delegation of authority form has
been completed.
Once randomised, the system will automatically gener-
ate a confirmation email, which will be sent to relevant
study staff in a blinded or unblinded format, depending
on their role in the study.
If it is not possible to use the randomisation system
randomisation may occur using the toss of a coin in order
to avoid losing the patient from the study. This should
only be needed, if at all, in specific and rare situations such
as the CTU server being inaccessible. This will be per-
formed by two people with heads denoting DCB, and tails
denoting placebo. The CTU must be informed of the coin
randomisation as soon as possible.
Study treatment
In the intervention arm, the second component is inser-
tion of a DCB (Bard Lutonix). This must be of identical
diameter to the plain balloon (Bard Dorado) and a mini-
mum of 1 cm longer than the plain balloon (Bard Dorado)
(5 mm at either end), inflated to nominal pressure at the
lesion location for a minimum duration of 1 minute.
Instructions for use of the DCB are stringently adhered
to to ensure appropriate preparation and handling of the
device.
In the control arm, an identical procedure is followed,
but using a placebo balloon that is not drug-coated (Bard
Ultraverse). This must be of identical diameter to the plain
balloon (Bard Dorado) and a minimum of 1 cm longer
than the plain balloon (Bard Dorado) (5 mm at either
end), inflated to nominal pressure at the lesion location
for a minimum duration of 1 minute.
If more than one plain balloon (Bard Dorado) is used
for the plain balloon fistuloplasty then the dimensions of
the placebo balloon (Bard Ultraverse) or drug-coated
balloon (Bard Lutonix) is matched to the plain balloon
with the larger diameter and/or the longer length.
In both arms, image overlay/roadmap will be uti-
lised to ensure that there is no geographical mismatch
between the segments treated with the high- and low-
pressure balloons.
A completion fistulogram is performed (completion
fistulogram II) to confirm that there is no angiographic-
ally visible effect after treatment with the drug-coated or
placebo balloon, according to the same specifications as
fistulogram I in Table 3. Procedural success is defined as
a residual stenosis of 30 % or less on completion fistulo-
gram II.
The data file(s) containing the initial pre-procedure
fistulogram and completion fistulograms I and II will
be sent to the lead study site with the patient’s name
replaced by the trial ID, and with each of the above
groups of images clearly identified. Completion fistu-
logram II will then be sent to the independent angio-
graphic laboratory for analysis.
Study assessments
These will occur every 3 months ± 1 month. Follow-up
will be variable but for a minimum of 1 year and a max-
imum of 3 years. These will involve a clinical assessment
to take place either face to face or via a telephone conver-
sation. Any face-to-face meetings will usually coincide
with dialysis to avoid additional patient travel.
Data recorded for each study assessment will include
the following: target lesion primary patency, access circuit
primary and cumulative patency, access circuit interven-
tions, patient medications and AEs.
At the 6-month study assessment, the trial team will
additionally collect information on fistula function and
check if referral for re-intervention is being considered
based on clinical concerns. If this is the case then a fistu-
logram ± plasty will be performed according to usual
clinical practice and the patient will not undergo a proto-
col fistulogram. If there are no clinical concerns related to
the fistula, then patients will be invited to undergo a
protocol fistulogram. Confirmation that there is no
contraindication to this protocol fistulogram will be ob-
tained from an appropriate doctor and documented.
Six-month protocol fistulogram
This will take place within 2 weeks of the 6-month study
assessment. If a patient has required a repeat fistulo-
plasty to the treatment segment at or before 6 months
then they will not undergo the 6-month protocol fistulo-
gram. All other patients will be invited to undergo a
protocol fistulogram 6 months after the index procedure
to acquire the data for the angiographic secondary end-
points. If a patient declines the 6-month protocol fistulo-
gram or does not have it for another reason, this will not
be considered a protocol violation and the patient may
continue in the study.
The 6-month protocol fistulogram must be performed
by a radiologist other than the one who performed the
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index procedure to ensure that they are blind to which
trial arm the participant belongs. With forward planning
this should be possible, but if it is not then the protocol
fistulogram should not be performed.
The 6-month protocol fistulogram will be a diagnostic
study only unless an unsuspected stenosis is identified
and the radiologist believes that it would be unethical
not to intervene. This will not be considered a protocol
violation and a fistula intervention form will need to be
completed.
The 6-month protocol fistulogram will be performed
according to the specifications in Table 2.
The 6-month protocol fistulogram will be considered
to be exclusively trial data. The result of the 6-month
protocol fistulogram will not be made available (verbally
or in writing) to the clinical team responsible for consid-
ering future referral of the patient for an intervention.
The images will also not be available on the local radi-
ology system. The images will be sent to the lead site in
order to be forwarded to the independent core labora-
tory with the patient’s name replaced by the trial ID.
Fistulograms performed for a clinical indication
The following applies only to patients who have not yet
reached the primary endpoint of the trial, and who are
referred for a potential re-intervention by the radiologist
who performed the study treatment and so is not blinded
to this. Pre-procedure fistulograms performed for a clin-
ical indication will follow the specifications in Table 2.
The image file will be sent to the lead site in order to
be forwarded to the independent core laboratory for
analysis with the patient details replaced by the trial
PIN. This will be sent regardless of whether the fistulo-
gram is followed by a fistuloplasty. This will allow us to
demonstrate that there is no bias in the final decision to
proceed, or not, with the repeat intervention.
End of study definition
The clinical trial will end when 211 patients have been
recruited and all patients have completed at least 1 year of
follow-up. The trial may be prematurely discontinued by
the sponsor, funder, chief investigator or Trial Steering
Committee (TSC) on the basis of new safety information
or for other reasons given by the Data Monitoring and
Ethics Committee (DMC), the TSC, and the Research and
Ethics Committee (REC). The trial may also be prema-
turely discontinued due to lack of recruitment or upon
advice from the TSC which will advise on whether to con-
tinue or discontinue the study and make a recommenda-
tion to the sponsor. If the trial is prematurely discontinued,
active participants will be informed and no further partici-
pant data will be collected.
Laboratory tests
There are no local laboratory tests that are required to
provide data that directly relate to trial endpoints. A 10-
ml blood sample will be requested at the time points
stated in the trial schedule, and is to be sent to the local
clinical laboratory for a full blood count and to check
the C-reactive protein level. If patients decline some or
all of these samples it will not be considered a protocol
violation.
Blood (up to 90 ml) may be taken at each of the time
points. These will be sent to the research laboratory of the
chief investigator (CI) where the blood will be separated.
Research blood samples should not be taken from patients
who are known to be hepatitis B surface antigen- (HbsAg),
hepatitis C IgG/RNA- or HIV-positive. Deoxyribonucleic
acid (DNA) and ribonucleic acid (RNA) will be stored.
Cells will be stored in aliquots in liquid nitrogen until
thawed for analysis. Serum and/or plasma samples will be
stored at −20 °C or −80 °C until thawed for analysis.
Transport, separation and storage will be according to
Standard Operating Procedures. It will not be a consid-
ered a protocol violation if any of the blood samples are
not taken, or are taken at different time points to those
specified and patients may continue in the study.
Independent core laboratory analysis
The completion fistulogram II (taken after treatment
with the DCB or placebo low-pressure balloon) will be
compared with the protocol 6-month fistulogram or
with the pre-procedure fistulogram taken prior to a clin-
ically driven re-intervention at the treatment segment if
this is before 6 months. These will be analysed by an
independent core laboratory for the angiographic sec-
ondary endpoints.
In addition, in patients who have not yet reached the pri-
mary endpoint of the trial, clinically-driven pre-procedure
fistulograms will be sent to the independent core laboratory
for analysis if they were performed by a radiologist
who is not blind to the study treatment. This will be
sent regardless of whether the fistulogram is followed
by a fistuloplasty.
Assessment of safety
We have been informed by the Medicines and Healthcare
products Regulatory Agency (MHRA) that the PAVE
protocol does not fall within the Clinical Trial Regula-
tions and, therefore, is not a drug trial. In addition, the
DCB is a CE-marked medical device, so prior regulatory
approval from the MHRA is not needed. Safety reporting
will be in keeping with the requirements for research
other than Clinical Trials of Investigational Medicinal
Products.
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Data Monitoring and Trial Steering Committees
The membership will be decided by the CI and approved
by the National Institute for Health Research (NIHR). The
DMC includes a statistician and two other independent
experts. They will receive a report of recruitment, serious
and non-serious adverse events and a summary of accu-
mulated clinical data from the trial statistician, and will
meet in person or by telephone. They will report to the
TSC who will usually meet in the 2 weeks following the
DMC meeting. The DMC will meet at least annually dur-
ing the study, approximately 2 weeks prior to the TSC.
Additional meetings may take place at the time of interim
analysis or in case of recruitment issues. The DMC is
advisory to the TSC. The DMC charter will be drafted and
agreed prior to recruitment. The trial statistician will
prepare reports to the DMC. The TSC will be convened in
the post-award period. The membership will be decided
by the CI and approved by the NIHR. The chair will be an
independent expert. Members will include the CI, a pa-
tient representative, and two other independent experts.
The TSC will meet at least annually during the study,
approximately 2 weeks after the DMC. Additional meet-
ings may take place at the time of interim analysis or in
case of recruitment issues. The TSC is an executive com-
mittee. Terms of reference of the TSC will be agreed and
documented prior to start of recruitment. The trial man-
ager will prepare reports to the TSC.
Ethics and regulatory approvals
Informed consent will be obtained from all participants.
The trial will be conducted in compliance with the princi-
ples of the Declaration of Helsinki (1996), the principles
of GCP and in accordance with all applicable regulatory
requirements including but not limited to the Research
Governance Framework. This protocol and related docu-
ments were approved by the London-Chelsea REC on 12
May 2015 (reference 15/LO/0638). The CI will submit a
final report to the sponsor and the REC at conclusion of
the trial. Annual progress reports will be submitted to the
main REC for the study.
Data handling
All samples will be anonymised before laboratory analysis.
No patient-related data will be held in research laborator-
ies. During the study, any paper documents will be held in
a locked filing cabinet in a locked office and retained for a
minimum of 5 years following the end of the study.
Clinical and research data for the study will be stored on
the eCRF system, hosted at the King’s College London
Clinical Trials Unit. The eCRF (InferMed MACRO) is
GCP and FDA 21 CFR Part 11 compliant. Data entry staff
at site will be provided with unique usernames and
passwords to the system and will be trained in data entry
by the trial manager. The trial manager will visit sites to
review data on the system, raise discrepancies and confirm
source data verification checks. All requests for access to
the data entry system must be authorised by the trial
manager. All requests for data exports must be authorised
by the trial statistician. The trial manager will work with
the CI and the trial statistician to ensure that data are
checked and cleaned on an ongoing basis and will confirm
that all data checks have been completed before database
lock. The investigators and the institutions will permit
trial-related monitoring, audits, REC review, and regula-
tory inspections (where appropriate) by providing direct
access to source data and other relevant documents (i.e. pa-
tients’ case sheets, blood test reports, X-ray reports). Record
keeping will be the responsibility of the investigators.
Discussion
We have presented the protocol of a multicentre RCT to
test whether use of DCBs will lead to preservation of
vascular access for haemodialysis with a reduction in
restenosis and the need for repeat fistuloplasties. There
is one previously published randomised trial in vascular
access for haemodialysis patients and the limitations of
this study have been discussed above in the Background
section [24]. Two recent observational reports give further
support to the suggestion that DCBs will be of benefit. A
single-centre study investigated DCBs for the management
of 20 juxta-anastomotic stenoses in radiocephalic fistulae of
10 patients. A different lesion in the same patient served
as the control [27]. This small study suggested an im-
proved target lesion revascularisation-free survival for
DCBs. In addition, in a retrospective study of recurrent
symptomatic central stenosis in 27 consecutive patients
with haemodialysis fistulas, custom-made DCBs were
suggested to show a benefit over plain balloons [28].
We are aware of two prospective randomised trials
that have been completed with results awaited. One is a
single centre study from Singapore (NCT01544907) and
includes 125 patients. It includes a mixture of AVGs and
AVFs and has a primary endpoint of angiographic late
lumen loss. In addition, a small randomised open-label
study from Canada (NCT01001676) includes 33 patients
with AVGs or AVFs and has 6-month primary patency
as the primary endpoint.
In contrast to these trials, our study is restricted to
patients with a native AVF in order to give a more de-
fined patient group. In addition, our trial design means
that patients and referring clinicians will be blinded to
the study treatment. Furthermore, the primary endpoint
is a clinical one that makes a difference to patients. We
have included two secondary angiographic endpoints,
which will be measured during a protocol fistulogram at
6 months post randomisation in patients who have not
met the primary endpoint prior to this. We anticipate
that the number of patients who will have had a repeat
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procedure within these 6 months will be fewer in the
DCB treatment group compared to the control group.
This means that the timing of the fistulogram used for
the secondary angiographic endpoints will, on average,
be later for the DCB treatment group. Therefore, any
improvement in late lumen loss or binary restenosis in
the DCB group will be despite this difference in timing,
rather than because of it. We anticipate that this trial
will provide rigorous data that will clarify whether DCBs
are of clinical benefit in haemodialysis patients with a
native AVF undergoing fistuloplasty.
Trial status
Recruitment started in November 2015.
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